In February 2026, what new drug, milsaperidone (Bysanti), was approved by the FDA for treating manic or mixed episodes associated with bipolar I disorder and schizophrenia?

In February 2026, the U.S. Food and Drug Administration (FDA) approved milsaperidone, marketed under the brand name Bysanti, for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for the treatment of schizophrenia in adults. This approval introduces a new chemical entity to the class of atypical antipsychotics, offering an additional therapeutic option for individuals living with these complex psychiatric conditions.

Bysanti is particularly interesting because it is an active metabolite of iloperidone, an antipsychotic previously approved by the FDA. This means that when milsaperidone is taken, it rapidly converts into iloperidone within the body, essentially leveraging the established efficacy and safety profile of the older drug. This pharmacokinetic bridging strategy allowed for a streamlined regulatory review process, building upon extensive clinical data already gathered for iloperidone.

The drug works by interacting with several key neurotransmitter receptors in the brain, including dopamine D2, serotonin 5-HT2A, and alpha-adrenergic receptors. By antagonizing these receptors, milsaperidone helps to modulate pathways implicated in mood, psychosis, and arousal, contributing to its therapeutic effects. The introduction of Bysanti is a significant development, providing clinicians and patients with another evidence-based tool to manage severe mood and psychotic symptoms, and potentially addressing unmet needs in behavioral health.